Advaxis Company Profile (NASDAQ:ADXS)

Analyst Ratings

Consensus Ratings for Advaxis (NASDAQ:ADXS) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.80 (208.84% upside)

Analysts' Ratings History for Advaxis (NASDAQ:ADXS)
Show:
DateFirmActionRatingPrice TargetActions
7/7/2016FBR & CoReiterated RatingOutperform$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Barclays PLCLower Price TargetOverweight$30.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2015MLV & Co.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Noble FinancialReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2015AegisReiterated RatingBuy -> PositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Advaxis (NASDAQ:ADXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
4/13/2016        
4/16/2015($0.31)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/23/2014($0.25)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Advaxis (NASDAQ:ADXS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.61)($0.61)($0.61)
Q3 20161($0.55)($0.55)($0.55)
Q4 20161($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Advaxis (NASDAQ:ADXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Advaxis (NASDAQ:ADXS)
DateHeadline
07/26/16 11:23 AMStock Update (NASDAQ:ADXS): Advaxis, Inc. Announces Completion of Second Dose-Escalation Cohort for Phase 1/2 ... - Smarter Analyst
07/26/16 07:18 AMPhase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort - [at noodls] - Part A expansion and Part B now enrolling for AXAL in combination with durvalumab for the treatment of advanced, recurrent or refractory HPV-associated cervical cancer and head & neck cancer PRINCETON, ...
07/25/16 07:58 PMAdvaxis : AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients
07/24/16 07:07 AMIs $25 Price Target Attainable For Advaxis, Inc. (NASDAQ:ADXS)? - Investor Newswire
07/23/16 02:20 PMEquity Roundup: Stock Performance Focus on Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/23/16 02:20 PMStock Displaying Signs of a Downtrend: Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/22/16 02:18 PMAnalyst Rating Trends to Observe: Community Health Systems, Inc. (NYSE:CYH) , Advaxis, Inc. (NASDAQ:ADXS) - Street Updates
07/22/16 02:18 PMTrading Examination: Performance check on Advaxis, Inc. (NASDAQ:ADXS) - TGP
07/22/16 06:31 AMADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
07/21/16 02:21 PMChecking in on Stock Volatility for: Advaxis, Inc. (NASDAQ:ADXS) - Engelwood Daily
07/21/16 02:21 PMAdvaxis, Inc. (NASDAQ:ADXS): Share Synopsis and Trading Review - Press Telegraph
07/21/16 02:21 PMStock Update (NASDAQ:ADXS): Advaxis, Inc.'s AXAL Receives Fast Track Designation by the FDA as Adjuvant ... - Smarter Analyst
07/21/16 10:57 AMAdvaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients
07/21/16 10:57 AMAdvaxis (ADXS) Granted FDA Fast Track Designation for AXAL
07/20/16 09:19 PMEMA committee classifies Advaxis’ Lm immunotherapy candidate, AXAL as advanced-therapy medicinal product
07/20/16 02:56 PMEquity Update - Focusing on Shares of Advaxis, Inc. (NASDAQ:ADXS) - Engelwood Daily
07/20/16 02:56 PMAdvaxis, Inc. (NASDAQ:ADXS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 10:27 AMSession Focus: Performance Watch on Shares of Advaxis, Inc. (NASDAQ:ADXS) - TGP
07/19/16 07:46 PMSession Focus - Highlighting Shares of: Advaxis, Inc. (NASDAQ:ADXS) - TGP
07/19/16 02:20 PMAdvaxis, Inc. (NASDAQ:ADXS): Stock Insight and Session Performance Spotcheck - Press Telegraph
07/19/16 02:20 PMInvestors are Intently Watching Shares of: Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/19/16 02:20 PMConsensus Analyst Target Price Check for Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/18/16 02:19 PMAdvaxis, Inc. (NASDAQ:ADXS) Taking a Look at the Current Company Impact Score - Press Telegraph
07/18/16 02:19 PMAdvaxis, Inc. (NASDAQ:ADXS) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 02:19 PMTracking Trading Performance for: Advaxis, Inc. (NASDAQ:ADXS) - TGP
07/18/16 02:19 PMMarket Motion Watch - Focus on Shares of: Advaxis, Inc. (NASDAQ:ADXS) - TGP
07/18/16 07:07 AMCompany Update (NASDAQ:ADXS): European Medicines Agency Committee Classifies Advaxis, Inc.'s Axalimogene ... - Smarter Analyst
07/18/16 06:32 AM7:32 am Advaxis announces that axalimogene filolisbac has been classified as an advanced-therapy medicinal product for the treatment of cervical cancer by the European Medicines Agency's Committee for Advanced Therapies -
07/18/16 06:30 AMEuropean Medicines Agency Committee Classifies Advaxis’ Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product - [GlobeNewswire] - PRINCETON, N.J., July 18, 2016-- Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac, ...
07/17/16 02:17 PMCompany Shares in Focus: Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/17/16 02:17 PMTrading Focus on Shares of: Advaxis, Inc. (NASDAQ:ADXS) - TGP
07/17/16 02:17 PMAre Analysts Bearish Advaxis, Inc. (NASDAQ:ADXS) After Last Week? - Consumer Eagle
07/17/16 02:17 PMAdvaxis, Inc. (NASDAQ:ADXS) Earnings Review and Target Watch - TGP
07/17/16 07:06 AMShares Moving Down on the Week: Advaxis, Inc. (NASDAQ:ADXS) - Engelwood Daily
07/17/16 07:06 AMStrong Sell Calls For Advaxis, Inc. (NASDAQ:ADXS) At 0 - Investor Newswire
07/16/16 02:20 PMStock Performance Check on : Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/15/16 06:38 PMShares Experiencing a Downtrend: Advaxis, Inc. (NASDAQ:ADXS) - TGP
07/15/16 06:38 PMCurrent Sentiment and Impact Score Watch:Advaxis, Inc. (NASDAQ:ADXS):Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/15/16 06:38 PMMoving Stock in Focus: Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/14/16 07:50 PMAdvaxis, Inc. (NASDAQ:ADXS) Analyst Average Stock Rating - Engelwood Daily
07/14/16 02:22 PMAnalysts are Watching Shares of: Advaxis, Inc. (NASDAQ:ADXS) - Telanagana Press
07/14/16 02:22 PMEquity Insight on Advaxis, Inc. (NASDAQ:ADXS) Shares - Telanagana Press
07/14/16 02:22 PMAdvaxis, Inc. (NASDAQ:ADXS): Stock Review and Performance Update - Press Telegraph
07/13/16 07:51 PMAdvaxis : Appoints Ranya Dajani as Vice President, Corporate Development
07/13/16 02:20 PMActive Share Performance Review for: Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/13/16 02:20 PMAdvaxis, Inc. (NASDAQ:ADXS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 10:26 AMStock Performance Summary on Shares of: Advaxis, Inc. (NASDAQ:ADXS) - Telanagana Press
07/13/16 10:26 AMCompany Sentiment Score Update:Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph
07/13/16 10:25 AMAdvaxis Appoints Ranya Dajani as Vice President, Corporate Development - Nasdaq
07/12/16 07:50 PMAdvaxis, Inc. (NASDAQ:ADXS) Company Stock Rating in Focus - Engelwood Daily

Social

About Advaxis

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company. The Company's immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company's immunotherapy candidates include Axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac (ADXS-HPV) is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV) associated cancers. ADXS-PSA is an Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (PSA) associated with prostate cancer. ADXS-HER2 is an Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADXS
  • CUSIP:
Key Metrics:
  • Previous Close: $7.90
  • 50 Day Moving Average: $8.27
  • 200 Day Moving Average: $7.97
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $275.80M
  • Beta: 1.55
  • Current Year EPS Consensus Estimate: $-2.14 EPS
  • Next Year EPS Consensus Estimate: $-2.08 EPS
Additional Links:
Advaxis (NASDAQ:ADXS) Chart for Tuesday, July, 26, 2016